ImmuCell (ICCC) Q2 2024 earnings summary

Executive summary

• Product sales rose 55% year-over-year to $5.47M in Q2 2024 and 82% to $12.73M for H1 2024, driven by increased supply, higher prices, and expanded production capacity nearing $30M annually.

• First Defense® remains the primary commercial product, with over 34 million doses sold and strong demand, while Re-Tain® is pending FDA approval and targets a $2B market.

• Backlog of orders stood at $7.9M as of August 6, 2024, down from $9.4M at year-end but up from $2.5M at the end of 2022.

• Remediation of production contamination events has enabled higher output, but gross margin improvement remains below the 40% target due to yield losses.

• Strategic priorities include growing First Defense® sales, achieving FDA approval for Re-Tain®, and proving Re-Tain® market acceptance.

Financial highlights

• Product sales for H1 2024 were $12.7M, up from $7.0M year-over-year; Q2 2024 sales were $5.47M, up 55% YoY.

• Gross margin for H1 2024 was $3.53M (28%), up from $1.35M (19%) in H1 2023; Q2 2024 gross margin was $1.23M (22%), down from 30% in Q2 2023.

• Net loss for H1 2024 was $1.97M ($0.25/share), improved from $3.69M ($0.48/share) in H1 2023; Q2 2024 net loss was $1.53M ($0.20/share).

• EBITDA for H1 2024 was -$340K, improved from -$2.2M year-over-year.

• Cash and equivalents were $1.3M as of June 30, 2024; debt (excl. LOC) was $11.3M.

Outlook and guidance

• Management targets $24M in 2024 sales, with a long-term goal to exceed $35M annually post-Re-Tain® launch.

• Gross margin is expected to improve as production stabilizes and process yields increase, with a 40% long-term target.

• FDA approval for Re-Tain® is pending resolution of contract manufacturer inspectional observations; controlled launch planned upon approval.

• Initiatives are underway to improve yield and gross margin following past contamination and yield losses.

• Investment in in-house formulation and aseptic filling for Re-Tain® is paused; approval of new process could occur two years after restart.